THE PORTFOLIO MANAGERS

thomas_pohjanen

Thomas Pohjanen

CEO and Partner at Excalibur Asset Management AB

Thomas graduated from Tulane University, New Orleans, Louisiana, USA, and holds a B.Sc. in Economics from Uppsala University. He has been active in the financial industry since 1986. From 1989 to 1993, Thomas was responsible for fixed income proprietary trading at the Nordbanken US branch, New York. He subsequently was head of MeritaNordbanken’s global fixed income trading in Stockholm until 2000. Since 2001, Thomas is part of Excalibur Fixed Income’s fund management team.

bjorn_suurwee

Björn Suurwee

Deputy CEO and Partner at Excalibur Asset Management AB

Björn holds a B.Sc in Mathematics from the University of New Hampshire, USA. He has been active in the financial industry since 1989. From 1989 to 1991, Björn was market maker in Swedish money market instruments at SEB. Between 1991 and 1997 he headed the interbank division at the asset management firm Aragon. From 1997 to 2000, Björn was head of money market at MeritaNordbanken in Stockholm. Since 2001, he is part of the Excalibur Fixed Income’s fund management team

The Team

Since its inception in 2001, the Excalibur Fixed Income Fund has been managed by Thomas Pohjanen and Björn Suurwee. The two managers first met at Nordea (then MeritaNordbanken) in 1997 and learned they shared the same approach to managing fixed income instruments. They also realised that their individual competencies were highly complementary, a good foundation for creating a solid return independent from market conditions.

In 2000, they left Nordea to launch their own hedge fund within Lancelot Asset Management. Since then, they have continued developing their individual strengths and created a successful concept. In 2006, Thomas and Björn left Lancelot with the support from Mellby Gård, to gain greater ownership in managing the fund. The Excalibur Fixed Income Fund and the management team have repeatedly received awards and nominations for generating long term stable performance with a low risk profile.